Friday’s Daily Piece: Dapagliflozin’s DAPA-CKD Results Led to FDA Breakthrough Therapy Designation for Chronic Kidney Disease

The results of the clinical trial, DAPA-CKD, which studied dapagliflozin (Farxiga) in adults with chronic kidney disease with or without type 2 diabetes on, has led the way for the FDA giving dapagliflozin breakthrough therapy designation (BTD) for adults chronic kidney disease with or without type 2 diabetes. Breakthrough therapy designation is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. 

To learn more about the findings of DAPA-CKD and the newly earned BTD, please click on links below.

https://www.healio.com/news/endocrinology/20200924/dapackd-dapagliflozin-prolongs-survival-in-ckd-with-without-type-2-diabetes?M_BT=4557970002905

https://www.healio.com/news/endocrinology/20201002/dapagliflozin-earns-breakthrough-therapy-designation-for-ckd-with-without-type-2-diabetes?M_BT=4557970002905

4 Main Complications From Farxiga | by Terry Crane | Medium
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#CKD #diabetes #FDA #dapagliflozin

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.

Leave a Reply

Your email address will not be published. Required fields are marked *